To enhance the anti-tumor response, PD-L1 inhibitors must bind to FcγR and C1q with high affinity to evoke potent ADCC and CDC to clear tumor cells, which indicates that IgG1 is the optimal structural basis of PD-L1 inhibitors. This evidence concerns the gene CD274 and neoplasm.